TBPH: Cost Reset And Cash Reserves Will Shape Post Ampreloxetine Future

Analysts nudged their average price target for Theravance Biopharma higher by about $0.33, reflecting updated models that remove ampreloxetine after the CYPRESS miss, while giving more weight to cost reductions, Yupelri and Trelegy cash flows, and a lower assumed future P/E multiple.

Analyst Commentary

Recent research shows a split view on Theravance Biopharma after the CYPRESS outcome and the decision to wind down ampreloxetine, with price targets reset and ratings shifting as analysts reassess what drives value from here.

Bullish Takeaways

Bullish analysts point to Yupelri and residual Trelegy rights as the core pillars of valuation, with existing commercial and royalty cash flows forming the basis of their models.
The planned reduction in R&D and G&A, with about US$70m in targeted cost savings versus 2025 OpEx, is seen as a key execution lever that could support earnings power if management delivers.
The reported US$326.5m cash position is viewed as providing meaningful runway through the reset, which reduces near term financing risk in bullish models.
Some bullish analysts highlight potential incremental upside from China royalties and future Yupelri milestones. They factor these into higher price targets even after removing ampreloxetine.

Bearish Takeaways

Bearish analysts focus on the loss of ampreloxetine as a growth driver. They remove it from their models and argue that there is limited visibility into new upside catalysts at this point.
Multiple rating downgrades, including moves to Neutral or Perform, reflect concern that the current story leans heavily on existing assets without a clear next pipeline engine.
Target cuts, such as resets to the mid-teens, underline caution around how much value to ascribe to future cash flows, especially after the Phase 3 CYPRESS study did not meet its primary endpoint.
Some bearish analysts question execution risk around the wind down of R&D and the broader reset. They flag that realizing cost savings while preserving long term growth options could be challenging.

What's in the News

Theravance Biopharma plans a restructuring that is expected to affect approximately 50% of its workforce, including a full wind down of the R&D organization and about a 50% reduction in G&A roles, with estimated one time cash severance costs of US$5 million to US$7 million (Company announcement).
Topline Phase 3 CYPRESS results for ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy did not meet the primary endpoint on the OHSA composite score. As a result, the company has decided to wind down the ampreloxetine program (Company announcement).
The Board's Strategic Review Committee is accelerating its ongoing review of alternatives to maximize shareholder value, including options such as a potential sale of the company, while cautioning that this process may not result in any transaction (Company announcement).
Theravance Biopharma is implementing an organizational restructuring aimed at reducing operating expenses by about 60% relative to preliminary 2025 actuals of approximately US$110 million. The company expects full run rate cost savings of roughly US$70 million to be in place by the third quarter of 2026, tied to a sharper commercial focus on YUPELRI (Company announcement).
Following the ampreloxetine decision, the company highlights its expected approximately US$400 million cash balance at the end of the first quarter of 2026, a 35% interest in YUPELRI, a potential US$100 million TRELEGY milestone and Irish tax attributes as key remaining sources of value under review (Company announcement).

Valuation Changes

Fair Value: The updated fair value estimate has risen slightly from $15.83 to $16.17 per share.
Discount Rate: The discount rate assumption is effectively unchanged, holding at about 6.98%.
Revenue Growth: The long-term revenue growth expectation has shifted from 4.78% growth to a 5.03% decline, indicating a more cautious revenue outlook.
Net Profit Margin: The assumed net profit margin has moved higher from 34.82% to 46.32%, reflecting a stronger focus on profitability and cost savings.
Future P/E: The future P/E multiple has been reduced from 31.33x to 26.00x, indicating a lower valuation multiple applied to projected earnings.

3 views

Key Takeaways

Sustained demand for key therapies and new product approvals support revenue growth, expanded margins, and enhanced operating leverage in both established and emerging markets.
Streamlined cost structure, controlled spending, and a robust cash position reduce financial risk while enabling reinvestment in pipeline assets and supporting future earnings growth.
Heavy reliance on a few products, reduced royalty streams, tough pricing pressures, and rising competition create significant risks to growth, margins, and revenue stability.

Catalysts

About Theravance Biopharma

A biopharmaceutical company, develops and commercializes of medicines in the United States.What are the underlying business or industry changes driving this perspective?

The advancing aging global population and rising prevalence of chronic diseases continue to drive increased demand for chronic and respiratory treatments, supporting YUPELRI's sustained double-digit sales growth and expanded profit margins, which are likely to have a positive impact on revenue and operating leverage.
The near-term potential for ampreloxetine, a precision medicine therapy in a rare neurogenic condition (MSA with nOH) with high unmet need and a targeted addressable US population, positions Theravance to capture outsized revenue and enjoy favorable pricing dynamics versus historical benchmarks, with significant implications for future top-line growth and net margins if successful.
Newly achieved YUPELRI approval in China, with the commercial launch being managed by Viatris at no incremental cost to Theravance, offers access to a large, expanding emerging-market customer base, creating forward-looking upside in royalty income and milestone payments without margin dilution from increased SG&A.
A streamlined, focused cost structure after recent restructuring, combined with disciplined R&D and SG&A spending (including stable prelaunch expenses and targeted future investments), is positioned to enhance operating margins and support improved earnings leverage as commercial and pipeline assets mature.
Strong cash position, expected near-term milestone inflows (up to $175 million from TRELEGY and YUPELRI), and profitable, recurring revenue streams reduce financial risk and enable reinvestment in growth opportunities or return of excess capital to shareholders, directly supporting net income stability and potential for future EPS expansion.

Theravance Biopharma Earnings and Revenue Growth

Theravance Biopharma Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Theravance Biopharma's revenue will decrease by 5.0% annually over the next 3 years.
Analysts assume that profit margins will shrink from 98.5% today to 46.3% in 3 years time.
Analysts expect earnings to reach $42.6 million (and earnings per share of $0.76) by about March 2029, down from $105.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $85.2 million in earnings, and the most bearish expecting $5.1 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.1x on those 2029 earnings, up from 7.2x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 16.6x.
Analysts expect the number of shares outstanding to grow by 2.98% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Theravance's revenue base remains highly concentrated: Aside from YUPELRI, much of its near-term value depends on successful approval and commercialization of ampreloxetine, leaving the company vulnerable to negative trial outcomes or underperformance of one key asset; revenue and earnings could become volatile if ampreloxetine fails to deliver as expected.
The company has divested its only substantial external royalty stream by selling its remaining interest in TRELEGY, meaning future cash inflows will depend more heavily on internal assets and milestone payments; longer term, this reduces recurring revenue diversification and heightens exposure to product-specific risks, impacting revenue stability and net margins.
The pricing and reimbursement environment for new rare disease drugs is increasingly challenging, with growing payer pushback in the U.S. and heightened scrutiny on value-based pricing-especially as ampreloxetine's price may benchmark against high-cost alternatives; this threatens expected revenue growth and margin realization even upon regulatory approval.
YUPELRI's future growth faces potential headwinds from increasing competition in the respiratory care market from both large pharmaceutical companies and generics (especially after patent expiry, despite protection to 2039), putting continued market share, pricing, and profitability at long-term risk.
Operating leverage and margin improvement appear dependent on keeping costs flat while scaling sales, but any failure to achieve ambitious sales targets, encounter larger-than-expected SG&A increases (post-ampreloxetine launch), or delays/shortcomings in the launch or market uptake of new therapies could erode anticipated profit margins and cash flow.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $16.17 for Theravance Biopharma based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $14.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $92.1 million, earnings will come to $42.6 million, and it would be trading on a PE ratio of 26.1x, assuming you use a discount rate of 7.0%.
Given the current share price of $14.9, the analyst price target of $16.17 is 7.8% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Theravance Biopharma?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Chronic And Respiratory Care Will Fuel Future Market Expansion